Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2815-2830

  Leibundgut, Gregor ^a,b   Scipione, Corey ^c   Yin, Huiyong ^d   Schneider, Matthias ^e   Boffa, Michael B ^c   Green, Simone ^a   Yang, Xiaohong ^a   Dennis, Edward ^a   Witztum, Joseph L ^a   Koschinsky, Marlys L ^c   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF WINDSOR   (Canada)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Kringles; Lipoproteins; Plasminogen

Indexed keywords

ANTIBODY; ANTIBODY E06; APOLIPOPROTEIN; LIPOPROTEIN; PHOSPHOLIPID; RECOMBINANT PROTEIN; TRYPSIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CONTROLLED STUDY; COVALENT BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOBLOTTING; IMMUNOREACTIVITY; LIPID OXIDATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; WESTERN BLOTTING;

KRINGLES; LIPOPROTEINS; PLASMINOGEN;

ANIMALS; APOLIPOPROTEINS A; BINDING SITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GORILLA GORILLA; HUMANS; LIPOPROTEIN(A); MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDATION-REDUCTION; PAN PANISCUS; PAN TROGLODYTES; PAPIO; PHOSPHOLIPIDS; PROTEIN BINDING; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84884160203     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M040733     Document Type: Article

References (63)

1. Dubé, J. B., M. B. Boffa, R. A. Hegele, and M. L. Koschinsky. 2012. Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23: 133-140.
2. Hoover-Plow, J., and M. Huang. 2013. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 62: 479-491.
3. Kronenberg, F., and G. Utermann. 2013. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273: 6-30.
4. McLean, J. W., J. E. Tomlinson, W. J. Kuang, D. L. Eaton, E. Y. Chen, G. M. Fless, A. M. Scanu, and R. M. Lawn. 1987. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330: 132-137.
5. Lawn, R. M., N. W. Boonmark, K. Schwartz, G. E. Lindahl, D. P. Wade, C. D. Byrne, K. J. Fong, K. Meer, and L. Patthy. 1995. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J. Biol. Chem. 270: 24004-24009.
6. Tsimikas, S., Z. Mallat, P. J. Talmud, J. J. Kastelein, N. J. Wareham, M. S. Sandhu, E. R. Miller, J. Benessiano, A. Tedgui, J. L. Witztum, et al. 2010. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol. 56: 946-955.
7. Erqou, S., A. Thompson, E. Di Angelantonio, D. Saleheen, S. Kaptoge, S. Marcovina, and J. Danesh. 2010. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J. Am. Coll. Cardiol. 55: 2160-2167.
8. Emerging Risk Factors Collaboration, S. Ergou, S. Kaptoge, P. L. Perry, E. Di Angelantonio, A. Thompson, I. R. White, S. M. Marcovina, R. Collins, S. G. Thompson, and J. Danesh. 2009. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 302: 412-423.
9. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al.; PROCARDIS Consortium. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
10. Kamstrup, P. R., A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 301: 2331-2339.
11. Tsimikas, S., and J. H. Hall. 2012. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60: 716-721.
12. Tsimikas, S., C. Bergmark, R. W. Beyer, R. Patel, J. Pattison, E. Miller, J. Juliano, and J. L. Witztum. 2003. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41: 360-370.
13. Edelstein, C., D. Pfaffinger, J. Hinman, E. Miller, G. Lipkind, S. Tsimikas, C. Bergmark, G. S. Getz, J. L. Witztum, and A. M. Scanu. 2003. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J. Biol. Chem. 278: 52841-52847.
14. Tsimikas, S., E. S. Brilakis, E. R. Miller, J. P. McConnell, R. J. Lennon, K. S. Kornman, J. L. Witztum, and P. B. Berger. 2005. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353: 46-57.
15. Tsimikas, S., and J. L. Witztum. 2008. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr. Opin. Lipidol. 19: 369-377.
16. Bergmark, C., A. Dewan, A. Orsoni, E. Merki, E. R. Miller, M. J. Shin, C. J. Binder, S. Horkko, R. M. Krauss, M. J. Chapman, et al. 2008. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49: 2230-2239.
17. Taleb, A., J. L. Witztum, and S. Tsimikas. 2011. Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark. Med. 5: 673-694.
18. van Dijk, R. A., F. Kolodgie, A. Ravandi, G. Leibundgut, P. P. Hu, A. Prasad, E. Mahmud, E. Dennis, L. K. Curtiss, J. L. Witztum, et al. 2012. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J. Lipid Res. 53: 2773-2790.
19. Fefer, P., S. Tsimikas, A. Segev, J. Sparkes, F. Otsuma, F. Kolodgie, R. Virmani, J. Juliano, T. Charron, and B. H. Strauss. 2012. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc. Revasc. Med. 13: 11-19.
20. Tsimikas, S., S. Kiechl, J. Willeit, M. Mayr, E. R. Miller, F. Kronenberg, Q. Xu, C. Bergmark, S. Weger, F. Oberhollenzer, et al. 2006. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J. Am. Coll. Cardiol. 47: 2219-2228.
21. Gong, Y., and J. Hoover-Plow. 2012. The plasminogen system in regulating stem cell mobilization. J. Biomed. Biotechnol. 2012: 437920.
22. Tsimikas, S., H. K. Lau, K. R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss. 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 109: 3164-3170.
23. Kiechl, S., J. Willeit, M. Mayr, B. Viehweider, M. Oberhollenzer, F. Kronenberg, C. J. Wiedermann, S. Oberthaler, Q. Xu, J. L. Witztum, et al. 2007. Oxidized phospholipids, lipoprotein(a), lipoproteinassociated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27: 1788-1795.
24. Tsimikas, S., P. Willeit, J. Willeit, P. Santer, M. Mayr, Q. Xu, A. Mayr, J. L. Witztum, and S. Kiechl. 2012. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassifi- cation of cardiovascular events. J. Am. Coll. Cardiol. 60: 2218-2229.
25. Leibundgut, G., K. Arai, A. Orsoni, H. Yin, C. Scipione, E. R. Miller, M. L. Koschinsky, M. J. Chapman, J. L. Witztum, and S. Tsimikas. 2012. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J. Am. Coll. Cardiol. 59: 1426-1437.
26. Mulichak, A. M., A. Tulinsky, and K. G. Ravichandran. 1991. Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9-A resolution. Biochemistry. 30: 10576-10588.
27. Koschinsky, M. L., J. E. Tomlinson, T. F. Zioncheck, K. Schwartz, D. L. Eaton, and R. M. Lawn. 1991. Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry. 30: 5044-5051.
28. Sangrar, W., and M. L. Koschinsky. 2000. Characterization of the interaction of recombinant apolipoprotein(a) with modified fi- brinogen surfaces and fibrin clots. Biochem. Cell Biol. 78: 519-525.
29. Hancock, M. A., M. B. Boffa, S. M. Marcovina, M. E. Nesheim, and M. L. Koschinsky. 2003. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol. Chem. 278: 23260-23269.
30. Feric, N. T., M. B. Boffa, S. M. Johnston, and M. L. Koschinsky. 2008. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lysplasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J. Thromb. Haemost. 6: 2113-2120.
31. Merki, E., M. J. Graham, A. E. Mullick, E. R. Miller, R. M. Crooke, R. E. Pitas, J. L. Witztum, and S. Tsimikas. 2008. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 118: 743-753.
32. Merki, E., M. Graham, A. Taleb, G. Leibundgut, X. Yang, E. R. Miller, W. Fu, A. E. Mullick, R. Lee, P. Willeit, et al. 2011. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 57: 1611-1621.
33. Schneider, M., J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al. 2005. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J. Lipid Res. 46: 769-778.
34. Tsimikas, S., M. Aikawa, F. J. Miller, Jr ., E. R. Miller, M. Torzewski, S. R. Lentz, C. Bergmark, D. D. Heistad, P. Libby, and J. L. Witztum. 2007. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 27: 175-181.
35. Boonmark, N. W., X. J. Lou, Z. J. Yang, K. Schwartz, J. L. Zhang, E. M. Rubin, and R. M. Lawn. 1997. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J. Clin. Invest. 100: 558-564.
36. Skålén, K., M. Gustafsson, E. K. Rydberg, L. M. Hultén, O. Wiklund, T. L. Innerarity, and J. Borén. 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 417: 750-754.
37. Szapacs, M. E., H. Y. Kim, N. A. Porter, and D. C. Liebler. 2008. Identification of proteins adducted by lipid peroxidation products in plasma and modifications of apolipoprotein A1 with a novel biotinylated phospholipid probe. J. Proteome Res. 7: 4237-4246.
38. Friedman, P., S. Horkko, D. Steinberg, J. L. Witztum, and E. A. Dennis. 2002. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J. Biol. Chem. 277: 7010-7020.
39. Boullier, A., P. Friedman, R. Harkewicz, K. Hartvigsen, S. R. Green, F. Almazan, E. A. Dennis, D. Steinberg, J. L. Witztum, and O. Quehenberger. 2005. Phosphocholine as a pattern recognition ligand for CD36. J. Lipid Res. 46: 969-976.
40. Seimon, T. A., M. J. Nadolski, X. Liao, J. Magallon, M. Nguyen, N. T. Feric, M. L. Koschinsky, R. Harkewicz, J. L. Witztum, S. Tsimikas, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2- dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12: 467-482.
41. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Horkko, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607.
42. Watson, A. D. 2006. Systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J. Lipid Res. 47: 2101-2111.
43. Fang, L., R. Harkewicz, K. Hartvigsen, P. Wiesner, S. H. Choi, F. Almazan, J. Pattison, E. Deer, T. Sayaphupha, E. A. Dennis, et al. 2010. Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J. Biol. Chem. 285: 32343-32351.
44. Harkewicz, R., K. Hartvigsen, F. Almazan, E. A. Dennis, J. L. Witztum, and Y. I. Miller. 2008. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J. Biol. Chem. 283: 10241-10251.
45. Luke, M. M., J. P. Kane, D. M. Liu, C. M. Rowland, D. Shiffman, J. Cassano, J. J. Catanese, C. R. Pullinger, D. U. Leong, A. R. Arellano, et al. 2007. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27: 2030-2036.
46. Li, Y., M. M. Luke, D. Shiffman, and J. J. Devlin. 2011. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ. Cardiovasc. Genet. 4: 565-573.
47. Arai, K., M. M. Luke, M. L. Koschinsky, E. R. Miller, C. R. Pullinger, J. L. Witztum, J. P. Kane, and S. Tsimikas. 2010. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis. 209: 498-503.
48. Hughes, S. D., X. J. Lou, S. Ighani, J. Verstuyft, D. J. Grainger, R. M. Lawn, and E. M. Rubin. 1997. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J. Clin. Invest. 100: 1493-1500.
49. Belczewski, A. R., J. Ho, F. B. Taylor, Jr ., M. B. Boffa, Z. Jia, and M. L. Koschinsky. 2005. Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysinebinding site in apolipoprotein(a) kringle IV type 10. Biochemistry. 44: 555-564.
50. Xia, J., L. F. May, and M. L. Koschinsky. 2000. Characterization of the basis of lipoprotein [a] lysine-binding heterogeneity. J. Lipid Res. 41: 1578-1584.
51. Scanu, A. M., D. Pfaffinger, J. C. Lee, and J. Hinman. 1994. A single point mutation (Trp72 → Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim. Biophys. Acta. 1227: 41-45.
52. Chang, M. K., C. J. Binder, Y. I. Miller, G. Subbanagounder, G. J. Silverman, J. A. Berliner, and J. L. Witztum. 2004. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J. Exp. Med. 200: 1359-1370.
53. Bieghs, V., S. M. Walenbergh, T. Hendrikx, P. J. van Gorp, F. Verheyen, S. W. Olde Damink, A. A. Masclee, G. H. Koek, M. H. Hofker, C. J. Binder, et al. 2013. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. Liver Int. 33: 1056-1061.
54. Ravandi, A., R. Harkewicz, G. Leibundgut, Y. I. Miller, E. A. Dennis, J. L. Witztum, and S. Tsimikas. 2011. Identification of oxidized phospholipids and cholesteryl esters in embolic protection devices post percutaneous coronary, carotid and peripheral interventions in humans. (Poster P385 at ATVB 2011 Scientific Sessions. April 28-30, 2011; Chicago, IL).
55. Chenivesse, X., T. Huby, J. Wickins, J. Chapman, and J. Thillet. 1998. Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57 → Asn mutation in kringle IV-10 is associated with poor fibrin binding. Biochemistry. 37: 7213-7223.
56. Scanu, A. M., L. A. Miles, G. M. Fless, D. Pfaffinger, J. Eisenbart, E. Jackson, J. L. Hoover-Plow, T. Brunck, and E. F. Plow. 1993. Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of kringle 4(37). J. Clin. Invest. 91: 283-291.
57. Miller, Y. I., S. H. Choi, P. Wiesner, L. Fang, R. Harkewicz, K. Hartvigsen, A. Boullier, A. Gonen, C. J. Diehl, X. Que, et al. 2011. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108: 235-248.
58. Hartvigsen, K., M. Y. Chou, L. F. Hansen, P. X. Shaw, S. Tsimikas, C. J. Binder, and J. L. Witztum. 2009. The role of innate immunity in atherogenesis. J. Lipid Res. 50 (Suppl) : S388 - S393.
59. Chang, M. K., C. J. Binder, M. Torzewski, and J. L. Witztum. 2002. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc. Natl. Acad. Sci. USA. 99: 13043-13048.
60. Weismann, D., K. Hartvigsen, N. Lauer, K. L. Bennett, H. P. Scholl, P. Charbel Issa, M. Cano, H. Brandstatter, S. Tsimikas, C. Skerka, et al. 2011. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. 478: 76-81.
61. Lichtman, A. H., C. J. Binder, S. Tsimikas, and J. L. Witztum. 2013. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J. Clin. Invest. 123: 27-36.
62. Leibundgut, G., J. L. Witztum, and S. Tsimikas. 2013. Oxidationspecific epitopes and immunological responses translational biotheranostic implications for atherosclerosis. Curr. Opin. Pharmacol. In press.
63. Kolski, B., and S. Tsimikas. 2012. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr. Opin. Lipidol. 23: 560-568.